Kelly Melissa Louise, Riordan Stephen M, Bopage Rohan, Lloyd Andrew R, Post Jeffrey John
Department of Infectious Diseases, Prince of Wales Hospital, Randwick, NSW, Australia.
Department of Medicine, The Albion Centre, Surry Hills, NSW, Australia.
PLoS One. 2018 Feb 13;13(2):e0192763. doi: 10.1371/journal.pone.0192763. eCollection 2018.
Achievement of the 2030 World Health Organisation (WHO) global hepatitis C virus (HCV) elimination targets will be underpinned by scale-up of testing and use of direct-acting antiviral treatments. In Australia, despite publically-funded testing and treatment, less than 15% of patients were treated in the first year of treatment access, highlighting the need for greater efficiency of health service delivery. To this end, non-invasive fibrosis algorithms were examined to reduce reliance on transient elastography (TE) which is currently utilised for the assessment of cirrhosis in most Australian clinical settings.
This retrospective and prospective study, with derivation and validation cohorts, examined consecutive patients in a tertiary referral centre, a sexual health clinic, and a prison-based hepatitis program. The negative predictive value (NPV) of seven non-invasive algorithms were measured using published and newly derived cut-offs. The number of TEs avoided for each algorithm, or combination of algorithms, was determined.
The 850 patients included 780 (92%) with HCV mono-infection, and 70 (8%) co-infected with HIV or hepatitis B. The mono-infected cohort included 612 men (79%), with an overall prevalence of cirrhosis of 16% (125/780). An 'APRI' algorithm cut-off of 1.0 had a 94% NPV (95%CI: 91-96%). Newly derived cut-offs of 'APRI' (0.49), 'FIB-4' (0.93) and 'GUCI' (0.5) algorithms each had NPVs of 99% (95%CI: 97-100%), allowing avoidance of TE in 40% (315/780), 40% (310/780) and 40% (298/749) respectively. When used in combination, NPV was retained and TE avoidance reached 54% (405/749), regardless of gender or co-infection.
Non-invasive algorithms can reliably exclude cirrhosis in many patients, allowing improved efficiency of HCV assessment services in Australia and worldwide.
扩大检测范围并使用直接抗病毒治疗是实现世界卫生组织(WHO)2030年全球丙型肝炎病毒(HCV)消除目标的基础。在澳大利亚,尽管检测和治疗由公共资金资助,但在治疗可及的第一年,接受治疗的患者不到15%,这凸显了提高医疗服务效率的必要性。为此,研究了非侵入性纤维化算法,以减少对目前在澳大利亚大多数临床环境中用于评估肝硬化的瞬时弹性成像(TE)的依赖。
这项回顾性和前瞻性研究包括推导队列和验证队列,研究了一家三级转诊中心、一家性健康诊所和一个基于监狱的肝炎项目中的连续患者。使用已发表的和新推导的临界值来测量七种非侵入性算法的阴性预测值(NPV)。确定了每种算法或算法组合可避免的TE数量。
850名患者中,780名(92%)为HCV单一感染,70名(8%)合并感染HIV或乙型肝炎。单一感染队列包括612名男性(79%),肝硬化总体患病率为16%(125/780)。“APRI”算法临界值为1.0时,NPV为94%(95%CI:91-96%)。新推导的“APRI”(0.49)、“FIB-4”(0.93)和“GUCI”(0.5)算法的NPV均为99%(95%CI:97-100%),分别可避免40%(315/780)、40%(310/780)和40%(298/749)的TE。联合使用时,NPV保持不变,无论性别或合并感染情况如何,TE避免率达到54%(405/749)。
非侵入性算法可以可靠地排除许多患者的肝硬化,提高澳大利亚和全球HCV评估服务的效率。